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Numerous pain-producing (pronociceptive) recep-
tors signal via phosphatidylinositol 4,5-bisphosphate
(PIP2) hydrolysis. However, it is currently unknown
which lipid kinases generate PIP2 in nociceptive dor-
sal root ganglia (DRG) neurons and if these kinases
regulate pronociceptive receptor signaling. Here,
we found that phosphatidylinositol 4-phosphate 5 ki-
nase type 1C (PIP5K1C) is expressed at higher levels
than any other PIP5K and, based on experiments
with Pip5k1c+/ mice, generates at least half of all
PIP2 in DRG neurons. Additionally, Pip5k1c haploin-
sufficiency reduces pronociceptive receptor sig-
naling and TRPV1 sensitization in DRG neurons as
well as thermal and mechanical hypersensitivity in
mouse models of chronic pain. We identified a small
molecule inhibitor of PIP5K1C (UNC3230) in a high-
throughput screen. UNC3230 lowered PIP2 levels in
DRG neurons and attenuated hypersensitivity when
administered intrathecally or into the hindpaw. Our
studies reveal that PIP5K1C regulates PIP2-depen-
dent nociceptive signaling and suggest that PIP5K1C
is a therapeutic target for chronic pain.
INTRODUCTION
Tissue inflammation and nerve injury cause the release of a com-
plex mix of chemicals that sensitize nociceptive dorsal root
ganglia (DRG) neurons and contribute to chronic pain (Basbaum
et al., 2009). These chemicals activate molecularly diverse pro-
nociceptive receptors found on DRG neurons and their axon
terminals. While these receptors represent attractive targets for
analgesic drug development, efforts to block individual pronoci-
ceptive receptors have not yet produced effective treatments for
chronic pain (Gold and Gebhart, 2010). This lack of efficacy
could reflect the fact that multiple pronociceptive receptors are
activated in the setting of chronic pain.
One approach to treat pain that bypasses this receptor
diversity is to target points where different signaling pathways836 Neuron 82, 836–847, May 21, 2014 ª2014 Elsevier Inc.converge. Indeed, drugs that block signaling proteins that are
several steps downstream from receptor activation, including
protein kinase Cε (PKCε) and mitogen-activated protein kinases
(MAPKs), reduce nociceptive neuron sensitization, thermal hy-
peralgesia, and mechanical allodynia in animal models (Aley
et al., 2000, 2001; Cesare et al., 1999; Cheng and Ji, 2008; Dai
et al., 2002; Ji et al., 2002, 2009). However, drugs that inhibit
PKCε or MAPKs have shown modest-to-no efficacy in treating
different pain conditions in humans (Anand et al., 2011; Cousins
et al., 2013; Ostenfeld et al., 2013; Tong et al., 2012). This limited
efficacy does not mean that PKCε or MAPK inhibitors cannot be
used to treat pain, as drugs can show limited-to-no efficacy for a
number of reasons, including the drugs may not engage their
molecular target in humans or the drugs may lack efficacy in
some pain conditions but not others.
Another convergence point, albeit one that has not been fully
explored in the context of treating pain, is immediately down-
stream of multiple pronociceptive receptors. Many pronocicep-
tive receptors, including Gq-coupled receptors, Gs-coupled
receptors (via EPAC), and receptor tyrosine kinases, initiate
signaling upon phospholipase C (PLC)-mediated hydrolysis of
the lipid secondmessenger PIP2 (Hucho et al., 2005). PIP2 hydro-
lysis produces diacylglycerol (DAG) and inositol-1,4,5-trisphos-
phate (IP3), which regulate nociceptive sensitization via multiple
pathways, including PKC-dependent modulation of ion channels
like TRPV1, MAPK activation, and IP3-mediated calcium influx
(Falkenburger et al., 2010; Gamper and Shapiro, 2007; Gold
and Gebhart, 2010; Rohacs et al., 2008; Tappe-Theodor et al.,
2012). PIP2 thus sits at a convergence point for diverse receptors
and signaling pathways that promote and maintain nociceptive
sensitization. In light of this information, we reasoned that itmight
be possible to reduce signaling through pronociceptive recep-
tors and reduce pain sensitization by inhibiting the lipid kinase
that generates the majority of all PIP2 in DRG neurons.
Type 1 phosphatidylinositol 4-phosphate 5-kinases (Pip5k1s)
generate PIP2 by phosphorylating the 5 position on the inositol
ring of phosphatidylinositol 4-phosphate [PI(4)P]. There are three
mammalian Pip5k1 genes (Pip5k1a, Pip5k1b, and Pip5k1c) (Ish-
ihara et al., 1998). Of these, Pip5k1c (also known as Pip5k1g) is
highly expressed in the brain (Wenk et al., 2001). PIP5K1C regu-
lates receptor-mediated calcium signaling, actin cytoskeletal
dynamics, endocytosis, and exocytosis (Di Paolo et al., 2004;
Legate et al., 2012; Ling et al., 2002; Unoki et al., 2012; van
Figure 1. PIP5K1C Is the Predominant PIP2
Synthesizing Enzyme in Embryonic and
Adult DRG Neurons
(A–C) In situ hybridization with gene-specific
probes using sections from adult mouse lumbar
DRG. Scale bar represents 50 mm.
(D and E) Double fluorescence in situ hybridization
using adult lumbar DRG. Confocal images. Scale
bars represent 50 mm.
(F and G) PIP5K1C protein levels in the DRG of
WT,Pip5k1c+/, andPip5k1c/embryonic (E17.5–
18.5) mice relative to b-actin. (F) Representative
western blots using two different antibodies (top [Di
Paoloetal., 2004],bottom[Haraetal., 2013])and (G)
representative quantification for the Di Paolo et al.
(2004) antibody; n = 2–3 embryos per genotype.
(H) PIP2 levels in embryonic (E17.5–18.5) DRG
quantified by a competitive binding enzyme-
linked immunosorbent assay (ELISA) from WT,
Pip5k1c+/, and Pip5k1c/mice. n = 10 embryos
per genotype.
(I and J) PIP5K1C protein levels in adult DRG.
(I) Western blots and (J) quantification; n = 3 per
genotype.
(K) PIP2 levels in DRG, spinal cord, and brain
(cerebral cortex) of adult male Pip5k1c+/+ and
Pip5k1c+/mice, quantified by ELISA. n = 10 mice
per genotype.
(L) Representative images of membrane PIP2
staining in small diameter DRG neurons cultured
from Pip5k1c+/+ and Pip5k1c+/ adult mice rela-
tive to NeuN.
(M) Quantification of the average perimeter
(membrane) intensity. n = 28 small diameter neu-
rons quantified per genotype. (G, H, J, K, and M)
All data are mean ± SEM. *p < 0.05, **p < 0.005,
***p < 0.0005.
See also Figure S1.
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Lipid Kinase Regulates Nociceptive Sensitizationden Bout and Divecha, 2009; Vasudevan et al., 2009; Volpicelli-
Daley et al., 2010; Wang et al., 2004, 2007; Xu et al., 2010; Yu
et al., 2011).
Previous studies examined the functions of Pip5k1c in the
brain of knockout mice (Di Paolo et al., 2004; Rodriguez et al.,
2012; Volpicelli-Daley et al., 2010; White et al., 2013). Homozy-
gous (Pip5k1c/) knockout mice have 50% less PIP2 in their
brains and die within 24 hr of birth due to impaired mobility
and an inability to feed (Di Paolo et al., 2004; White et al.,
2013). These data suggest a critical role for PIP5K1C in gener-
ating PIP2 in neurons and in nervous system development. In
contrast, heterozygous (Pip5k1c+/) mice are viable, reproduce
normally, have normal levels of PIP2 in the brain and showed
no phenotypes in an extensive battery of tests, includingmultiple
tests of neurological function (Di Paolo et al., 2004; White et al.,
2013). The only phenotype observed thus far in Pip5k1c+/mice
is high-frequency (>20 kHz) hearing loss (Rodriguez et al., 2012),
a phenotype ascribed to Pip5k1c haploinsufficiency in nonsen-
sory cells of the auditory system.Neuron 82, 836–When we initiated our studies, it was
unknown which enzymes generated
PIP2 in nociceptive DRG neurons or ifthese enzymes regulated nociception. Here, we report that
PIP5K1C is expressed in nearly all DRG neurons, generates at
least half of all PIP2 in the DRG, and regulates nociceptive sensi-
tization in response to diverse stimuli that cause pain. Our
studies validate PIP5K1C as an analgesic drug target and iden-
tify a PIP5K1C inhibitor that attenuates pain in animal models.
RESULTS
PIP5K1C Generates at Least Half of All PIP2 in DRG
Neurons
To determinewhichPip5k1swere expressed in theDRG,we per-
formed in situ hybridization with probes for the three known
mammalian Pip5k1 genes. We found that Pip5k1c was ex-
pressed at higher levels in adult mouse DRG than the two other
Pip5k1 genes and was expressed in nearly all DRG neurons (Fig-
ures 1A–1C). PIP5K1C is also present in the brain at higher levels
than PIP5K1A and PIP5K1B (Akiba et al., 2002; Wenk et al.,
2001). Consistent with widespread expression in all DRG847, May 21, 2014 ª2014 Elsevier Inc. 837
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Lipid Kinase Regulates Nociceptive Sensitizationneurons, based on in situ hybridization, Pip5k1c was expressed
in virtually all peptidergic (96.7%; n = 220 counted) and nonpep-
tidergic (96.1%; n = 210 counted) nociceptive neurons, marked
by Calcitonin gene-related peptide-alpha (Cgrp) and Prostatic
acid phosphatase (Pap), respectively (Figures 1D and 1E)
(McCoy et al., 2013; Zylka et al., 2008). Using a recently devel-
oped antibody (Hara et al., 2013), we found that PIP5K1C was
present on the plasma membrane and in the cytoplasm of
most DRGneurons (Figures S1A–S1C available online). PIP5K1C
was highly colocalized with PAP (98.1%; n = 2,672 counted),
CGRP (97.5%; n = 2,094 counted), and TRPV1 (92.2%; n =
1,915 counted), markers of nociceptive neurons (Figures S1D–
S1L). Moreover, PIP5K1C was expressed in human DRG at
levels comparable to CGRP (intensity values of 311 and 346,
respectively, from Affymetrix GeneChip experiments).
We then quantified PIP5K1C protein and PIP2 levels in the
DRG of wild-type (WT; Pip5k1c+/+), Pip5k1c+/, and Pip5k1c/
embryonic (E17.5–E18.5) mice. We found that PIP5K1C protein
and PIP2 levels were reduced (by 50%) in the DRG of
Pip5k1c+/ embryonic mice (Figures 1F–1H). No PIP5K1C pro-
tein was detectable in DRG from Pip5k1c/ embryonic mice,
confirming complete gene knockout and that both antibodies
used in our study specifically recognized PIP5K1C (Figures 1F
and 1G). In addition, PIP2 was reduced by 70% in DRG from
Pip5k1c/ embryonic mice (Figure 1H).
Unlike Pip5k1c/ mice that die at birth, Pip5k1c+/ mice live
into adulthood and reproduce normally (Di Paolo et al., 2004).
Therefore, we quantified PIP5K1C protein and PIP2 levels in
the DRG from Pip5k1c+/ adult mice and WT littermate controls.
PIP5K1C protein was reduced by 40% and PIP2 levels were
reduced by 50% in the DRG of Pip5k1c+/ mice (Figures 1I
and 1K). In contrast, PIP2 was not reduced in spinal cord or brain
from adult Pip5k1c+/ mice (Figure 1K). Likewise, using a
different quantification method, PIP2 was not reduced in the
brain of embryonic Pip5k1c+/mice (Di Paolo et al., 2004; Volpi-
celli-Daley et al., 2010). In addition, we used immunofluores-
cence staining to examine PIP2 levels at the membrane of
cultured DRG neurons taken from adult mice. Quantification of
the average perimeter (membrane) staining intensity in confocal
images revealed that membrane PIP2 levels were reduced by
50% in small-to-medium diameter (%27 mm) neurons of
Pip5k1c+/ mice compared to WT controls (Figures 1L and
1M). Taken together, our data indicate that PIP5K1C generates
at least half of all PIP2 in the DRG, including in small-to-medium
diameter, presumably nociceptive, DRG neurons. Moreover, our
data indicate that PIP2 is reduced in DRG of Pip5k1c
+/ adult
mice, but is not reduced in other regions of the nervous system
that process pain and somatosensory stimuli, namely spinal
cord and brain.
Pip5k1c Haploinsufficiency Attenuates Pronociceptive
Receptor Signaling
Diverse molecules cause pain by activating pronociceptive G
protein-coupled receptors (GPCRs) in DRG neurons. Because
PIP2 levels in the membrane were reduced by 50% in DRG
neurons, we hypothesized that pronociceptive GPCRs that
couple to phospholipases and PIP2 hydrolysis would signal
less effectively in Pip5k1c+/ mice. To test this hypothesis we838 Neuron 82, 836–847, May 21, 2014 ª2014 Elsevier Inc.used the ratiometric calcium (Ca2+) indicator dye Fura-2-AM to
quantify lysophosphatidic acid (LPA) and 17-phenyl trinor pros-
taglandin E2 (17-PT PGE2) evoked calcium responses in small-
to-medium diameter DRG neurons. LPA evokes Ca2+ influx in
small-to-medium diameter DRG neurons and, when injected
intrathecally (i.t.), produces a chemically-induced form of neuro-
pathic pain that is dependent on LPA1 receptor activation (Elmes
et al., 2004; Inoue et al., 2004). 17-PT PGE2 is a selective agonist
for Gq-coupled prostanoid receptors, a class of receptors that
are implicated in pain hypersensitivity following inflammation
(Kassuya et al., 2007; Minami et al., 1994). Following stimulation
with LPA or 17-PT PGE2, calcium responses (quantified as area
under the curve [AUC]) were blunted in Pip5k1c+/ neurons
compared to WT controls (Figures 2A–2D). Importantly, these
signaling deficits could be restored to WT levels by delivering
excess PIP2 to Pip5k1c
+/ neurons just prior to imaging (Figures
2A–2D). These data suggest that the signaling deficits observed
in Pip5k1c+/ neurons were the result of reduced PIP2 levels and
were not due to poor cell health or PIP2-independent signaling
deficits. Moreover, KCl-evoked Ca2+ responses, which reflect
activation of voltage-gated calcium channels, were not altered
(Figure 2A, data not shown). The percentage of neurons re-
sponding to either ligand (LPA responders: mean 22.2% ±
2.9% for WT and 24.1% ± 3.7% for Pip5k1c+/; 17-PT PGE2 re-
sponders: 6.0% ± 1.2% for WT and 4.7% ± 1.1% for Pip5k1c+/)
and the average diameter of responding neurons was not signif-
icantly different between WT and Pip5k1c+/ cultures (data not
shown). We also found that delivering excess PIP2 to WT neu-
rons did not elevate LPA- or 17-PT PGE2-evoked calcium re-
sponses beyond control levels, suggesting that PIP2 levels are
already saturated in WT neurons under our culture conditions.
Collectively, our data reveal that PIP5K1C regulates signaling
downstream from two pronociceptive receptors, one associated
with neuropathic pain and the other with inflammatory pain.
Moreover, rescue experiments revealed that Pip5k1c regulates
calcium signaling in DRG neurons via a PIP2-dependent mecha-
nism, placing PIP5K1C upstream of multiple signaling pathways
implicated in pain sensitization (Figure 2E).
Pip5k1c Haploinsufficiency Reduces Ligand-Induced
Nocifensive Behaviors
LPA and 17-PT PGE2 induce GPCR-mediated nociceptive re-
sponses when injected into the hindpaw (Kassuya et al., 2007;
Renba¨ck et al., 1999, 2000). To determine if these compounds
signal less effectively in Pip5k1c+/ mice, we injected LPA
(4.1 mg) or 17-PT PGE2 (1.2 mg) into one hindpaw then monitored
the duration of licking for 5 min. We found that Pip5k1c+/ mice
spent less time licking their ligand-injected hindpaws when
compared to WT littermates (Figure 2F). Reduced licking was
not due to motor impairment, as there were no significant differ-
ences between WT and Pip5k1c+/ mice in the rotarod assay
and gait was not impaired (stride or stance; Figures S2A–S2C).
Moreover, acute responses to innocuous mechanical touch
were not impaired in Pip5k1c+/ mice (Figure S2D).
There was also no loss of nociceptive neurons or terminals in
spinal cord of Pip5k1c+/ mice (determined by immunostaining
for CGRP and IB4-binding, markers of nociceptive neurons;
Figures S3A–S3J). Excitatory synaptic transmission between
Figure 2. Pip5k1c Haploinsufficiency Re-
duces Ligand-Evoked Nociceptive Sig-
naling In Vitro and Nocifensive Licking
In Vivo
(A–D) Calcium responses (A and C) and quantifi-
cation (B andD). Cultured adult DRG neuronswere
stimulated with 10 mM LPA (A and B) or 10 mM 17-
PT PGE2 (C and D) for 90 s, washed with HBSS for
120 s to remove the ligand, then stimulated for 30 s
with 100 mM KCl to confirm neuron identity (not
shown for 17-PT PGE2). Cultures were incubated
with 2 mM carrier or 2 mM Carrier + 2 mM PIP2 for
15 min prior to calcium imaging. Number of neu-
rons quantified is indicated in the bar graph. All
data are mean ± SEM. *p < 0.05, ***p < 0.0005.
(E) Model. PIP5K1C generates PIP2 that is hydro-
lyzed downstream of pronociceptive receptor
activation. Ca2+ influx and PKC activation con-
tribute to nociceptive sensitization. Pip5k1c hap-
loinsufficiency reduces the amount of PIP2 that is
available for signaling in DRG neurons.
(F) Time spent licking for the first 5 min after in-
jecting vehicle, 4.1 mg LPA, or 1.2 mg 17-PT PGE2
into the left hindpaw of adult WT and Pip5k1c+/
male mice. n = 10 per genotype per agonist.
(A–D and F) All data are mean ± SEM. *p < 0.05,
**p < 0.005.
See also Figures S2 and S3.
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impaired in Pip5k1c+/ mice, assessed by measuring excitatory
field potential (fEPSP) amplitude in spinal cord slices after stim-
ulating the dorsal root with a suction electrode (Street et al.,
2011). Specifically, we found no significant differences between
genotypes in fEPSP amplitude at different stimulus strengths
(Figure S3K), following synaptic depletion (Figures S3L and
S3M) or during synaptic recovery (Figure S3N). These data
also ruled out the possibility that synaptic transmission or synap-
tic vesicle trafficking was impaired in Pip5k1c+/ mice. Instead,
our data suggest that reduced nocifensive licking in Pip5k1c+/
reflects reduced pronociceptive receptor activation in vivo.
Pip5k1c Haploinsufficiency Attenuates TRPV1
Activation and Sensitization
PIP2 levels also affect the activity and sensitization of the capsa-
icin and noxious heat receptor TRPV1 (Lukacs et al., 2007;
Rohacs et al., 2008). To determine if Pip5k1c haploinsufficiency
affected TRPV1 activation, we stimulated cultured DRG neurons
from WT and Pip5k1c+/ mice with a high concentration of
capsaicin (1 mM) then monitored calcium responses. We found
that capsaicin-evoked calcium responses were blunted in DRG
neurons from Pip5k1c+/ mice (Figure 3A) and that addition of
exogenous PIP2 to Pip5k1c
+/ neurons restored capsaicin-Neuron 82, 836–evoked calcium responses to WT levels
(Figures 3A and 3B). These data are
consistent with the literature showing
that PIP2 is required for full activity when
TRPV1 is activated with a high concentra-
tion of capsaicin (Lukacs et al., 2007;
Rohacs et al., 2008). To evaluate TRPV1sensitization by a GPCR agonist, we stimulated DRG neurons
with a submaximal capsaicin concentration (100 nM; to limit
the effects of Ca2+-induced desensitization), applied the GPCR
agonist LPA (1 mM), and then stimulated with capsaicin again
to assess TRPV1 activity. We found that LPA sensitized TRPV1
activity in neurons cultured from WT mice (AUC value increased
from 6.3 ± 1.5 to 8.9 ± 1.5; unpaired t test, p < 0.05) (Figure 3C). In
contrast, LPA failed to sensitize TRPV1 in neurons cultured from
Pip5k1c+/ mice (AUC value decreased from 8.8 ± 2.0 to 3.6 ±
0.7; suggesting TRPV1 was desensitized) (Figure 3C). This likely
reflected normal desensitization of TRPV1 caused by repeated
capsaicin pulses (Loo et al., 2012). Consistent with this possibil-
ity, we found that repeated application of capsaicin (without
adding LPA) caused desensitization of TRPV1 (data not shown).
There was no significant difference in AUC values between WT
and Pip5k1c+/ neurons following the first application of this
low (100 nM) dose of capsaicin, consistent with previous litera-
ture showing that TRPV1 activity is less affected by changes in
PIP2 levels at low capsaicin concentrations (Lukacs et al.,
2007; Rohacs et al., 2008).
Next, we evaluated how Pip5k1c haploinsufficiency affected
TRPV1-mediated nociception in vivo. Injection of capsaicin
(intraplantar) produced mechanical allodynia in WT mice but
not thermal hyperalgesia (Figure 3D, data not shown), consistent847, May 21, 2014 ª2014 Elsevier Inc. 839
Figure 3. Pip5k1c Haploinsufficiency Reduces TRPV1-Mediated
Nociceptive Signaling In Vitro and In Vivo
(A and B) Capsaicin-evoked calcium responses (A) and quantification (B) of
cultured adult DRG neurons. Neurons were stimulated with 1 mM capsaicin for
90 s, washed with HBSS for 280 s, then stimulated for 30 s with 100 mMKCl to
confirm neuron identity. Cultures were incubated with 2 mM carrier or 2 mM
carrier + 2 mM PIP2 for 15 min prior to calcium imaging. Number of neurons
quantified is indicated in the bar graph.
(C) Capsaicin-evoked (Cap, gray, 100 nM) calcium responses before and after
incubating with LPA. Average traces for 156 WT neurons and 143 Pip5k1c+/
neurons.
(D) Mechanical sensitivity before and 30 min after intraplantar injection of 2 mg
capsaicin. n = 10 mice per genotype.
(E) Restrained hot plate assay. n = 30 mice per genotype.
(A–E) All data are mean ± SEM. *p < 0.05, **p < 0.005, ***p < 0.0005.
See also Figure S3.
Figure 4. Pip5k1c Haploinsufficiency Attenuates Thermal and
Mechanical Sensitization inModels of Inflammatory Pain andNeuro-
pathic Pain
(A and B) Thermal (radiant heating; Hargreaves assay) (A) and mechanical
(electronic von Frey) (B) sensitivity in LPA-induced neuropathic pain model.
LPA (1 nmol in 0.9% saline, i.t.) administered at the indicated time (arrow) to
adult WT and Pip5k1c+/ mice. n = 11 male mice per genotype.
(C and D) Thermal (C) and mechanical (D) sensitivity in the spared nerve injury
model of neuropathic pain. Contralateral hindpaw served as a control. n = 10
male mice per genotype.
(E and F) Thermal (E) and mechanical sensitivity (F) in CFA inflammatory pain
model. CFA (20 ml) was injected into one hindpaw. Contralateral paw was not
injected and served as a control. n = 10 male mice per genotype.
All data are mean ± SEM. Asterisks indicate significant difference betweenWT
andPip5k1c+/micebyaone-wayANOVA. *p<0.05, **p<0.005, ***p<0.0005.
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induced mechanical allodynia was significantly blunted in
Pip5k1c+/ mice (Figure 3D). Pip5k1c+/ mice also exhibited
increased withdrawal latencies at 45C, 50C, and 55C relative
to WT mice in the restrained hot plate assay (Figure 3E). Taken
together, these data suggest that Pip5k1c is required for appro-
priate activation and sensitization of TRPV1 and for normal
responsiveness to noxious heat.
Pip5k1c Haploinsufficiency Impairs Thermal and
Mechanical Sensitization in Models of Chronic Pain
Pronociceptive receptor activation can sensitize animals to
noxious thermal and mechanical stimuli. Because pronocicep-
tive receptors signaled less effectively in vitro and in vivo, we hy-
pothesized that thermal and mechanical sensitization might be
blunted in Pip5k1c+/ mice following inflammation or injury.840 Neuron 82, 836–847, May 21, 2014 ª2014 Elsevier Inc.Indeed, thermal hyperalgesia and mechanical allodynia were
enduringly attenuated inPip5k1c+/mice inmodels of chemically
induced neuropathic pain (i.t. injection of 1 nmol LPA), neuro-
pathic pain caused by spared-nerve ligation and inflammatory
pain followingan intraplantar injectionof complete Freund’s adju-
vant (CFA) (Figures 4A–4F). There were no significant differences
in the contralateral (noninflamed/noninjured) paw between WT
and Pip5k1c+/ mice, and there were no significant differences
in either paw at baseline (prior to LPA injection, nerve injury, or
inflammation). Taken together, these data suggest that Pip5k1c
regulates nociceptive sensitization in three different models of
chronic pain, with initiating events at three different anatomical
locations (intrathecal, peripheral nerves, and hindpaw).
Identification of a Small Molecule PIP5K1C Inhibitor that
Reduces Membrane PIP2 Levels and Reduces
Pronociceptive Receptor Signaling
At the time we began our study, there were no small molecule
inhibitors of PIP5K1C or any other lipid kinase that directly
Figure 5. Identification of UNC3230 as a
Selective Small Molecule PIP5K1C Inhibitor
(A) High-throughput screen is based on incu-
bating fluorescein conjugated PI(4)P (substrate)
with recombinant human PIP5K1C and then
measuring product formation using a microfluidic
mobility shift assay (LabChip).
(B) Representative traces showing substrate and
product peak separation in assay performed with
and without a small molecule inhibitor (UNC3230;
10 mM).
(C) UNC3230 structure and IC50 dose-response
curve, using LabChip assay.
(D) Selectivity of UNC3230 relative to a diverse
panel of kinases, using ProfilerPro (48 kinases)
and KINOMEscan (100 kinases) assays. Table S1
lists all kinases that were tested. Circle size and
color reflects percent activity/binding remaining in
the presence of UNC3230 (10 mM) relative to
controls. Branches without circles denote kinases
that were not tested. AGC, containing PKA,
PKG, PKC families; CAMK, calcium/calmodulin-
dependent protein kinase; CK1, casein kinase 1;
CMGC, containing CDK, MAPK, GSK3, CLK
families; STE, homologs of yeast Sterile 7, Sterile
11, Sterile 20 kinases; TK, tyrosine kinase; TKL,
tyrosine kinase-like. Image generated using
TREEspot Software Tool and reprinted with
permission from KINOMEscan, a division of
DiscoveRx.
(E–G) KINOMEscan competitive binding assays
with multiple doses of UNC3230, presented from
(E) strongest Kd to (G) weakest Kd. (C, E, F, and G)
All data are mean ± SEM.
See also Figure S4.
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complimentary method to validate targets when compared to
genetic methods and can establish target tractability for drug
discovery efforts (Weiss et al., 2007), we set out to identify a
selective small molecule inhibitor of PIP5K1C. Accordingly, we
developed a high-throughput microfluidic mobility shift assay
that separates fluorescein conjugated PI(4)P (substrate) from
fluorescein conjugated PIP2 (product) (Figures 5A and 5B). We
used this assay to screen a kinase-focused library (5,000 com-
pounds) for inhibitors of recombinant human PIP5K1C (data not
shown, assay development and screen will be described in a
subsequent article; human and mouse PIP5K1C are 96% iden-
tical at the amino acid level within the kinase domain and 92%
identical across the entire protein). From this screen, we identi-
fied UNC3230 [5-(cyclohexanecarboxamido)-2-(phenylamino)
thiazole-4-carboxamide] that had an IC50 of 41 nM using the
microfluidic mobility shift assay (Figure 5C). To assess selec-
tivity, we screened UNC3230 against 148 kinases (see Experi-
mental Procedures), covering all major branches of the kinome
(Figure 5D). Remarkably, UNC3230 inhibited (ProfilerPro assays)Neuron 82, 836–8or competitively interacted (DiscoveRX
binding assays) with only five other ki-
nases at our relatively high (10 mM)
screening concentration (using 10%activity/binding remaining relative to control as the cutoff for
each kinase group, except lipid kinases, where a more stringent
35% of control cutoff was used) (Figure 5D; Table S1). Notably,
UNC3230 did not interact with PIP5K1A at 10 mM, a PIP5K family
member that is highly similar (69% amino acid identity across the
entire protein and 82% identity within the kinase catalytic
domain) to PIP5K1C. Based on dose-responses with the five ki-
nases that were inhibited by UNC3230 at the 10 mM screening
concentration, UNC3230 showed selectivity (Kd < 0.2 mM; using
competitive binding assays) for PIP5K1C and PIP4K2C (phos-
phatidylinositol 5-phosphate 4-kinase, type II, gamma) (Figures
5E–5G). PIP5K1C and PIP4K2C directly generate PIP2, albeit
using different substrates; PI(4)P versus PI(5)P, respectively (Fig-
ure S4). UNC3230 represents a selective inhibitor for these lipid
kinases. Moreover, UNC3230 did not inhibit any of the other lipid
kinases that regulate phosphoinositide levels, including phos-
phatidylinositol 4,5-bisphosphate 3-kinases (PIK3s, also known
as PI3Ks) (Table S1; Figure S4). Note, PIP4K2C should not be
confused with phosphatidylinositol 4-kinases (PI4Ks). PI4Ks
generate PI(4)P from phosphatidylinositol and can be inhibited47, May 21, 2014 ª2014 Elsevier Inc. 841
Figure 6. UNC3230 Reduces Membrane
PIP2 Levels in DRG Neurons and GPCR
Signaling
(A) PIP2 antibody staining of WT DRG neurons
after incubating with vehicle (0.002% DMSO) or
100 nM UNC3230 for 20 hr. Costained with the
neuronal marker NeuN (blue).
(B) Quantification of the average perimeter
(membrane) intensity. n = 30–40 neurons per
condition.
(C) LPA-evoked calcium response in WT DRG
neurons after incubating with vehicle or the
indicated concentrations of UNC3230 for 20 hr.
After stimulation, cultures were washed with
HBSS for 120 s to remove LPA, then stimulated
for 30 s with 100 mM KCl to confirm neuron
identity.
(D) Quantification of the LPA-evoked calcium
response by measuring the AUC of each re-
sponding neuron. Number of neurons quantified
is indicated in bar graph. (B–D) Data are mean ±
SEM. *p < 0.05, ***p < 0.0005.
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sen et al., 1998).
Inhibition of PIP5K1C and/or PIP4K2C would be predicted to
reduce PIP2 levels, so we assessed how UNC3230 affected
PIP2 levels in DRG neurons by using the PIP2-specific antibody.
We found that membrane PIP2 levels were significantly reduced
by 45% in DRG neurons treated with 100 nM UNC3230
(2-fold above the IC50) relative to vehicle controls (Figures 6A
and 6B). PI(4)P is present at 10-fold higher concentration over
PI(5)P in cells (Delage et al., 2013), making UNC3230 more likely
to affect PIP2 that is generated by PIP5K1C. In addition, we
found that UNC3230 significantly reduced LPA-evoked calcium
signaling in cultured DRG neurons relative to vehicle (Figures 6C
and 6D). Collectively, our data indicate that UNC3230 represents
a pharmacological probe that can be used to inhibit two lipid
kinases that directly generate PIP2. Moreover, our data suggest
that UNC3230 blunts pronociceptive receptor signaling in
DRG neurons in a manner that is analogous to Pip5k1c
haploinsufficiency.
UNC3230 Has Antinociceptive Effects when Injected
Intrathecally or into an Inflamed Hindpaw
Next, we monitored sensitivity in WT mice before and shortly
after i.t. or intraperitoneal (i.p.) administration of UNC3230. We
found that UNC3230 (2 nmol in 20% DMSO) significantly
increased noxious heat-evoked paw withdrawal latency for
2 hr after i.t. injection (Figure 7A), indicating an antinociceptive
effect. UNC3230 did not have an acute effect on mechanical
sensitivity (Figure 7B) and did not exhibit antinociceptive activity
when administered i.p. (Figure S5A). This lack of activity via the
i.p. route could reflect different pharmacokinetic properties
following systemic versus localized (i.t. or into hindpaw, see
below) drug delivery. To evaluate dose-dependence, we admin-
istered UNC3230 at 1, 2, and 3 nmol (i.t.). We did not observe
antinociceptive activity at 1 nmol (in 20% DMSO) but observed842 Neuron 82, 836–847, May 21, 2014 ª2014 Elsevier Inc.antinociceptive activity at 2 nmol (in 20%DMSO) that was similar
to 3 nmol (in 50% DMSO) (Figure 7A and data not shown). In
contrast, an inactive analog that is structurally similar to
UNC3230 (by addition of a methyl group to the primary amide)
did not exhibit thermal antinociceptive activity (Figure S5B), sug-
gesting the antinociceptive activity of UNC3230 reflects on-
target engagement of PIP5K1C (Figure S5B). Lastly, UNC3230
(2 nmol, i.t.) did not affect performance in the rotarod assay
(Figure S5C).
Given that UNC3230 blunted LPA-evoked signaling, and that
LPA enduringly enhances thermal and mechanical sensitivity
by activating LPA receptors over a brief 3 hr critical period (Ma
et al., 2009), we next evaluated the extent to which UNC3230
could reduce LPA-evoked thermal and mechanical hypersensi-
tivity. We administered UNC3230 (2 nmol; i.t.; versus vehicle)
then 1 hr later coinjected 1 nmol LPA with UNC3230 (2 nmol,
i.t.; versus vehicle). UNC3230 significantly blunted thermal hy-
peralgesia and mechanical allodynia compared to vehicle (Fig-
ures 7C and 7D). Next, we administered UNC3230 (2 nmol; i.t.)
2 hr before and 2 hr after injecting CFA into one hindpaw. We
found that UNC3230 significantly blunted thermal hyperalgesia
and mechanical allodynia in the CFA-inflamed hindpaw (relative
to vehicle control) but did not affect thermal or mechanical sensi-
tivity in the control (noninflamed) hindpaw over a multiday time
course (Figures 7E and 7F). To determine if UNC3230 had anti-
nociceptive effects in animals with ongoing inflammation, we in-
jected CFA into one hindpaw and then 48 hr later injected
UNC3230 (2 nmol; i.t.). UNC3230 significantly reduced existing
CFA-induced thermal hyperalgesia (relative to vehicle control)
(Figure 7G). UNC3230 did not affect existing mechanical allody-
nia when administered following CFA inflammation (data not
shown). Additionally, peripheral administration of UNC3230
(8 nmol, into the CFA-inflamed hindpaw), reduced thermal hy-
peralgesia (Figure 7H). Taken together, these data suggest
UNC3230 could be used to block the initiation of chronic pain,
Figure 7. UNC3230 Reduces Thermal and
Mechanical Sensitization in Models of
Chronic Pain
(A and B) Thermal (A) and mechanical (B) sensi-
tivity of WT mice after administering vehicle or
2 nmol UNC3230 (i.t.). Arrow indicates injection.
n = 10 male mice per group. (A) One-way ANOVA
with post hoc Bonferroni correction was used to
compare differences between treatment groups
for the 5 hr time course and at each hour. Black
asterisks indicate significance at individual time
points. ANOVA for the 5 hr time course, p = 0.0045.
(C and D) Thermal (C) and mechanical (D) sensi-
tivity of WT mice in the LPA-induced neuropathic
pain model. Vehicle or 2 nmol UNC3230 were
administered i.t. One hour later, vehicle or 2 nmol
UNC3230 was administered i.t. with 1 nmol LPA.
n = 10 male mice per group. One-way ANOVA
were used to assess treatment effect over the
7-day time course (black asterisks).
(E and F) Thermal (E) and mechanical (F) sensitivity
of WTmice in the CFAmodel of inflammatory pain.
Vehicle or 2 nmol UNC3230 were administered i.t.
Two hours later, CFA was injected into one hind-
paw of each animal. The other hindpaw was not
inflamed and served as a control. Vehicle or 2 nmol
UNC3230 was administered (i.t.) 2 hr after CFA
injection. n = 10 male mice per group. One-way
ANOVA were used to assess treatment effect over
the 7-day time course (black asterisks).
(G and H) Thermal sensitivity of WT mice in the
CFA model of inflammatory pain. CFA was in-
jected into one hindpaw of each animal. The other
hindpawwas not inflamed and served as a control.
(G) Two days post-CFA injection, vehicle or 2 nmol
UNC3230 was administered i.t. n = 10 male mice
per group. (H) One day post-CFA injection, vehicle
or 8 nmol UNC3230 was administered into the
inflamed hindpaw. n = 10mice per group. (G) One-
way ANOVA was used to assess treatment effect
in the noninflamed paw over the 5 hr time course
following injection (gray asterisk). All data are
mean ± SEM. *p < 0.05, **p < 0.005. (H) One-way
ANOVA were used to assess treatment effect over
the 7-day time course (black asterisks).
See also Figure S5.
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Pip5k1c haploinsufficiency, and can reduce established pain
hypersensitivity.
DISCUSSION
Our study provides evidence that PIP5K1C generates at least
half of all PIP2 in DRG neurons and is a critical regulator of noci-
ceptive signaling and sensitization, including thermal and
mechanical hypersensitivity in models of neuropathic and in-
flammatory pain, two common forms of chronic pain in humans.
Our conclusions are supported by experiments with Pip5k1c+/
mice and with a small molecule inhibitor of PIP5K1C. Pip5k1c
haploinsufficiency reduced PIP2 levels in adult DRG by 50%
without affecting PIP2 levels in adult brain or spinal cord (Fig-
ure 1K), making it unlikely that the phenotypes we observed
were due to Pip5k1c haploinsufficiency in other regions of thenervous system. Moreover, spinal delivery of UNC3230 recapit-
ulated these antinociceptive phenotypes, suggesting that local-
ized inhibition of PIP5K1C in adults (and not during development)
is sufficient to reduce nociceptive sensitization.
With the possible exceptions of our intrathecal LPA experi-
ment and intraplantar experiment (Figures 4A, 4B, and 7H), in
no cases was sensitization restored to baseline levels in
Pip5k1c+/ mice or following UNC3230 administration. This
could reflect the fact that GPCR signaling was reduced, but
not eliminated, in neurons from Pip5k1c+/ mice and following
UNC3230 treatment. Moreover, there are likely additional en-
zymes in DRG that generate PIP2 and contribute to pronocicep-
tive receptor signaling. In support of this possibility, PIP2 levels
were not reduced to zero in DRG from Pip5k1c/ (embryonic)
mice (Figure 1H). There are additional signaling pathways and
cellular mechanisms that contribute to nociceptive sensitization
(Basbaum et al., 2009; Gold and Gebhart, 2010) and some ofNeuron 82, 836–847, May 21, 2014 ª2014 Elsevier Inc. 843
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and PIP2.
Intrathecal injections target DRG and spinal cord (Luo et al.,
2005). Our efforts to measure small and possibly localized
changes in PIP2 levels in DRG following intrathecal injection
were unsuccessful (data not shown). Thus, we cannot rule out
the possibility that UNC3230 affects nociceptive sensitization
by inhibiting PIP5K1C in the DRG and/or spinal cord (PIP5K1C
is expressed by spinal neurons but is not expressed by spinal
microglial cells; Allen Brain Atlas and data not shown). However,
given that UNC3230 had antinociceptive effects when injected
intrathecally as well as peripherally into the hindpaw, our data
suggest that central or peripheral inhibition of PIP5K1C, presum-
ably in primary sensory neurons or their afferents, is sufficient to
reduce nociceptive responses. Moreover, PIP2 levels were
reduced in DRG but not spinal cord or brain of Pip5k1c+/
mice, suggesting the antinociceptive phenotypes in Pip5k1c+/
mice were due to reduced activity of PIP5K1C in primary sensory
neurons.
As for why PIP2 levels were reduced in DRG of Pip5k1c
+/
mice but not spinal cord or brain, we speculate this reflects a
greater dependence on Pip5k1c in DRG relative to these other
tissues. In support of this idea, PIP2 levels were not reduced in
the brain of Pip5k1c+/ mice (Figure 1K) (Volpicelli-Daley et al.,
2010), but were reduced by 50% in the brain of embryonic
Pip5k1c/ mice (Volpicelli-Daley et al., 2010; Wang et al.,
2007). Thus, PIP2 levels in the central nervous system appear
to be insensitive to Pip5k1c haploinsufficiency. Additionally,
PIP2 levels were not reduced in the brain of embryonic Pip5k1a,
Pip5k1b double knockout mice, suggesting other enzymes be-
sides Pip5k1a, Pip5k1b, or Pip5k1c generate PIP2 in the nervous
system (Volpicelli-Daley et al., 2010). This greater dependence
on Pip5k1c in DRG makes this lipid kinase a particularly attrac-
tive target for analgesic drug development, as inhibition of
PIP5K1C has the potential to lower PIP2 levels in primary sensory
neurons to a greater extent than in the brain.
PIP5K1C Modulates Pronociceptive Receptor Signaling
via a PIP2-Dependent Mechanism
PIP2-dependence was supported by the fact that addition of
PIP2 rescued signaling deficits in Pip5k1c
+/ neurons. Others
similarly found that PIP2 addition rescued histamine-evoked cal-
cium responses in HeLa cells following Pip5k1c knockdown
(Wang et al., 2004). ATP-evoked calcium release from purinergic
receptors was significantly blunted in Pip5k1c+/ lateral nonsen-
sory cells (Rodriguez et al., 2012), further indicating that Pip5k1c
regulates receptor signaling. Furthermore, our data reveal that
Pip5k1c haploinsufficiency eliminates GPCR-mediated sensiti-
zation of TRPV1 (Figure 3C).
Pip5k1c regulates many additional processes downstream of
PIP2, including actin dynamics, synaptic vesicle release, and
NMDA-induced AMPA receptor endocytosis (Rusinova et al.,
2013; To´th et al., 2012; Unoki et al., 2012; van den Bout and Di-
vecha, 2009). We ruled out the possibility that neurotransmission
was impaired between sensory neurons and spinal neurons in
Pip5k1c+/mice, making it unlikely that vesicle recycling deficits
accounted for reduced behavioral sensitization. However, we
cannot exclude the possibility that other mechanisms down-844 Neuron 82, 836–847, May 21, 2014 ª2014 Elsevier Inc.stream of PIP2 are impaired in Pip5k1c
+/ mice. Future studies
will be needed to assess the relative contribution of these down-
stream mechanisms to nociceptive deficits in Pip5k1c+/ mice.
PIP5K1C Is an Analgesic Drug Target
The antinociceptive phenotypes in Pip5k1c+/ mice motivated
us to develop a high-throughput screen for PIP5K1C inhibitors.
From this screen, we identified UNC3230, a compound that
inhibited PIP5K1C in the nanomolar range and reduced receptor
signaling and nociceptive sensitization analogous to Pip5k1c
haploinsufficiency. While we evaluated the specificity of
UNC3230 relative to a large panel of kinases, we cannot exclude
the possibility that UNC3230 inhibits kinases that were not
available for testing, including additional kinases that generate
PIP2. Given that UNC3230 reduced PIP2 levels in DRG and had
antinociceptive activity in vivo, whereas an inactive close analog
of UNC3230 did not have antinociceptive activity, these data
suggest that UNC3230 has on-target biochemical effects.
UNC3230 showed selectivity for PIP5K1C and PIP4K2C, two
lipid kinases that directly generate PIP2. The DiscoveRx Selec-
tivity Profile score for UNC3230 was 0.12 (on a scale from 0 to
1.0) (Karaman et al., 2008). To put this value in context, of 38
kinase inhibitors (several of them FDA-approved) benchmarked
in this assay at 3 mM (Karaman et al., 2008), a majority (n = 22)
were less selective than UNC3230.
Our genetic and pharmacological data validate PIP5K1C as a
therapeutic target for chronic pain; however, further optimization
of hits from our high-throughput screen is warranted. For
example, UNC3230 has a narrow efficacy window and low solu-
bility in appropriate vehicles that limited our ability to perform
dose-responses in vitro and in vivo. These shortcomings may
be overcome through subsequentmedicinal chemistry optimiza-
tion, particularly given that PIP5K1C inhibitors could provide an
alternative to opioid and nonsteroidal antiinflammatory analge-
sics. Moreover, PIP5K1C inhibitors will likely have uses that
extend beyond the nociceptive system, such as to study how
transient PIP5K1C inhibition affects other processes linked to
PIP5K1C.
There are a number of additional enzymes that could affect
PIP2 levels in DRG neurons, including lipid kinases other than
PIP5K1C, phosphatases and lipid transporters. Our current
study suggests these additional enzymes represent attractive
targets for analgesic drug development. In support of this idea,
a functional-genomics study in Drosophila identified phospho-
lipid signaling and lipid kinases as key regulators of heat
nociception (Neely et al., 2012). This study also found that
Pip5k1a/ mice (not Pip5k1c) displayed hypersensitivity to
noxious heat and capsaicin. However, given that Pip5k1a is ex-
pressed at much lower levels in DRG (Figure 1A) and does not
contribute to PIP2 levels in the central nervous system (Volpi-
celli-Daley et al., 2010), precisely how and where Pip5k1a regu-
lates heat nociception in mice is unclear.
Human Implications
Humans carrying heterozygous null mutations in Pip5k1c (i.e.,
PIP5K1C+/ humans) develop normally and appear healthy (Nar-
kis et al., 2007). Because humans apparently can tolerate a life-
long reduction in PIP5K1C gene dosage, drugs that transiently
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larly in adults—the age group that suffersmost fromchronic pain.
The high-frequency hearing loss seen in Pip5k1c+/ mice is not
likely to be an issue in humans because humans cannot hear
above 20 kHz (Brant and Fozard, 1990). In contrast, PIP5K1C/
humans develop lethal congenital contracture syndrome type 3,
which is characterized bymuscle atrophy, joint contractures, and
death within 24 hr of birth (Narkis et al., 2007). The human pheno-
type closely mimics the perinatal lethality observed in the
Pip5k1c/ mice (Di Paolo et al., 2004). It is currently unknown
whether PIP5K1C+/ humans have reduced pain responses, as
we found with Pip5k1c+/mice. Future studies with these human
carriers have the potential to directly assess the importance of
PIP5K1C in human pain perception.
Intriguingly, the individuals that carry the PIP5K1C mutation
(PIP5K1C+/) are Bedouins and live in the Negev desert of
Israel—an environment that is arid and subject to extreme tem-
peratures. Like sickle-cell anemia, where heterozygotes (car-
riers) have a survival advantage in regions where malaria is
endemic, mutations in PIP5K1C might provide a survival advan-
tage in the desert, where somatosensory stimuli can be extreme.
EXPERIMENTAL PROCEDURES
Animals
All procedures involving vertebrate animals were approved by the Institutional
Animal Care and Use Committee at the University of North Carolina at Chapel
Hill.Pip5k1c+/micewere provided by Pietro DeCamilli at Yale University (also
available from The Jackson Laboratory, 008515) (Di Paolo et al., 2004). All mice
were backcrossed to C57BL/6 mice for at least ten generations.
Immunostaining
Lumbar DRG and spinal cord were dissected from adult (6- to 8-week-old)
male mice and immunostained as previously described (McCoy et al., 2013;
Zylka et al., 2008).
ELISA PIP2 Quantification
PI(4,5)P2 mass ELISA was purchased from Echelon Biosciences (K-4500) and
performed according to the manufacturer’s instructions with the following
alterations. Lumbar DRG (L3-L5, bilateral), lumbar spinal cord, and cerebral
cortex were dissected from adult male mice (6- to 8-week-old) and all DRG
were dissected from embryos (E17.5–18.5). All tissue was frozen immediately
on dry ice. Tissue was homogenized and sonicated prior to lipid extraction.
DRG samples were diluted 1:40 and spinal cord and brain samples were
diluted 1:200 prior to use in the ELISA assay. Bicinchoninic acid (BCA) protein
determination assay (ThermoScientific, 23225) was completed for each sam-
ple following the manufacturer’s instructions. Protein content for each sample
was used for normalization.
Neuron Culture and Calcium Imaging
All DRG were dissected from 3- to 8-week-old male mice following decapita-
tion and cultured as described (see Supplemental Experimental Procedures).
Calcium imaging of dissociated neurons was completed as described previ-
ously using Fura 2-acetoxymethyl ester (2 mM; F1221, Invitrogen) (McCoy
et al., 2013).
Behavioral Assays
Pronociceptive ligands (4.1 mg LPA; 1.2 mg 17-PT PGE2, in 0.9% saline) were
injected into the left hindpaw and the amount of time spent licking was
measured for 5min. Thermal andmechanical sensitivityweremonitored before
and 30 min after capsaicin (2 mg) injection. Thermal sensitivity was measured
using a Plantar Test apparatus (IITC) to heat each hindpaw and the latency
for hindpaw removalwas recorded.Onemeasurementwas taken for eachhind-paw to determine the withdrawal latency in seconds. The radiant heat source
intensity was calibrated so that the average withdrawal latency for WT mice
was 10 s. Cut off time was 20 s. Mechanical sensitivity was measured using
an electronic von Frey apparatus (IITC) and a semiflexible tip. Three measure-
ments for each hindpawwere taken and averaged to determine the withdrawal
threshold in grams. For the restrained hot plate test, animals were restrained by
scruffing and the right hindpaw was placed on a metal surface of the indicated
noxious temperature. The latency for the animal to withdrawal (lift, shake, or
jump) its hindpaw was recorded. Inflammatory (CFA) and neuropathic (LPA
and spared nerve injury) models of chronic pain were performed as described
previously (Ma et al., 2009; Shields et al., 2003; Zylka et al., 2008). Intrathecal
injections (5 ml) were performed in unanesthetizedmice using the direct lumbar
puncture method (Fairbanks, 2003). UNC3230 was prepared at a final concen-
tration of 0.4 mM (2 nmol per 5 ml) in 20% DMSO or 0.6 mM in 50% DMSO for
intrathecal injections. UNC3230 was prepared at a final concentration of
0.4 mM in 20% DMSO for intraplantar injections (20 ml per hindpaw; 8 nmol
total). For intraperitoneal injections, 5 mM UNC3230 was prepared in 90%
corn oil and 10% ethanol and administered at 20 mg/kg.
Small Molecule Inhibitor Screen
N-terminal His6-tagged full-length (90 kDa) recombinant human PIP5K1C
(Millipore 14-845) was incubated for 10min in the presence or absence of small
molecules in assay buffer (50 mM MOPS, 500 mM sodium cholate, 10 mM
magnesium chloride, and 25 mM sodium chloride) in 384-well Nunc assay
plates. Fluorescein conjugated substrate (PI(4)P; Cayman Chemical,
9000655) and ATP at the Km concentration for PIP5K1C (15 mM) were added
to the assay plates and incubated for 40 min. Reactions were stopped using
90 mM EDTA. Fluorescein conjugated PIP2 and remaining PI(4)P were sepa-
rated and quantified using the LabChip EZ Reader II microfluidic mobility shift
assay (PerkinElmer). Validation of the assay was performed in duplicate
using the library of pharmacologically active compounds (LOPAC; Sigma), giv-
ing a r2 value of 0.965. We used this assay to screen a focused kinase library
(5,000 compounds), which contained UNC3230.
Selectivity Screening
Two different assays were used to assess selectivity. ProfilerPro (PerkinElmer)
was used to assess selectivity of UNC3230 on 48 kinases. For the ProfilerPro
assay, UNC3230 was added to reaction-ready (384-well) assay plates
(PerkinElmer) containing each of the 48 kinases in duplicate and incubated
for 15 min. Matching fluorescent substrates for each kinase (also provided in
reaction-ready 384-well plates) and ATP at the Km for each kinase were added
then the plate was incubated for 90 min. Fluorescent substrates and products
were separated and quantified using the LabChip EZ Reader II microfluidic
mobility-shift assay (PerkinElmer). Data for this assay are reported as percent
of control (product produced in the absence of UNC3230).
The DiscoveRx KINOMEscan competitive binding assay was used to quan-
titatively measure interactions between UNC3230 and 100 different kinases.
Briefly, UNC3230 and each DNA-tagged kinase were added simultaneously
to 384-well plates containing immobilized ligands for each of the 100 kinases
tested. Plates were incubated for 1 hr and the amount of kinase bound to the
immobilized ligand was quantified using quantitative PCR (qPCR) and the
associated DNA tag. Binding interactions were determined by the amount of
kinase bound to the immobilized ligand. Competitive interactions between
the kinase and UNC3230 would prevent binding of the kinase to the immobi-
lized ligand. Data for this assay are reported as percent of control (binding of
a control compound to the kinase).
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